Medically reviewed by Drugs.com. Last updated on Dec 2, 2018.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Fleet Bisacodyl: 10 mg/30 mL (37 mL)
Bisac-Evac: 10 mg (1 ea, 8 ea, 12 ea, 50 ea, 100 ea, 500 ea, 1000 ea)
Biscolax: 10 mg (12 ea [DSC], 100 ea)
Dulcolax: 10 mg (4 ea, 8 ea, 16 ea, 28 ea, 50 ea)
The Magic Bullet: 10 mg (10 ea, 100 ea)
Generic: 10 mg (12 ea, 50 ea, 100 ea)
Tablet Delayed Release, Oral:
Bisacodyl EC: 5 mg
Bisacodyl EC: 5 mg [contains corn starch, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]
Bisacodyl EC: 5 mg [contains corn starch, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake, methylparaben, propylparaben]
Bisacodyl EC: 5 mg [contains corn starch, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake, methylparaben, propylparaben, sodium benzoate]
Bisacodyl EC: 5 mg [contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]
Bisacodyl EC: 5 mg [contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake, methylparaben, propylparaben, sodium benzoate]
Dulcolax: 5 mg [contains fd&c yellow #10 (quinoline yellow), methylparaben, propylparaben, sodium benzoate]
Ex-Lax Ultra: 5 mg [contains fd&c yellow #6 (sunset yellow), methylparaben]
Fleet Laxative: 5 mg [DSC]
GoodSense Bisacodyl EC: 5 mg [contains corn starch, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]
Womens Laxative: 5 mg [contains fd&c blue #1 aluminum lake, sodium benzoate, tartrazine (fd&c yellow #5)]
Brand Names: U.S.
- Bisac-Evac [OTC]
- Bisacodyl EC [OTC]
- Biscolax [OTC]
- Correct [OTC]
- Ducodyl [OTC]
- Dulcolax [OTC]
- Ex-Lax Ultra [OTC]
- Fleet Bisacodyl [OTC]
- Fleet Laxative [OTC] [DSC]
- GoodSense Bisacodyl EC [OTC]
- The Magic Bullet [OTC]
- Womens Laxative [OTC]
- Laxative, Stimulant
Stimulates peristalsis by directly irritating the smooth muscle of the intestine, possibly the colonic intramural plexus; alters water and electrolyte secretion producing net intestinal fluid accumulation and laxation
Oral, rectal: Systemic, 10 years and Adolescents: 5 to 10 mg once daily
Children 6 to 1 /2 suppository) once daily
Children ≥12 years and Adolescents: 10 mg once daily
Enema: Children ≥12 years and Adolescents: 10 mg once daily
Alternate dosing: Limited data available (Tabbers [NASPGHAN/ESPGHAN] 2014): Suppository/enema:
Children ≥2 to 10 years: 5 mg ( 1 /2 suppository) once daily
Children >10 years and Adolescents: 5 to 10 mg once daily
Oral: Administer with water. Swallow tablet whole; do not break, chew, or crush; do not administer within 1 hour of antacids, milk, or dairy products.
Enema: Shake well; remove protective shield, insert tip into rectum with slight side to side movement; squeeze the bottle until nearly all liquid expelled (some liquid will remain in unit after use). Gently remove the unit, a small amount of liquid will remain in unit after use.
Suppository: Remove foil, insert into rectum with pointed end first. Retain in rectum for 15 to 20 minutes.
Tablet: Do not administer within 1 hour of milk, dairy products, or an antacid.
Oral: Store at 20°C to 25°C (68°F to 77°F); protect from humidity.
Rectal: Store at 2 weeks occurs, or if you have already used a laxative, including bisacodyl, for >1 week. Use may cause stomach discomfort, faintness, rectal burning, and mild cramps. Discontinue use and consult a health care provider if use >1 week is needed.
Systemic exposure following maternal use of bisacodyl is limited. Plasma concentrations of BHPM (the active metabolite of bisacodyl) are low (median: 61 ng/mL; range: 20 to 118 ng/mL) and the pharmacokinetics are highly variable following oral doses of 10 mg/day for 7 days to women immediately postpartum (Friedrich 2011).
Treatment of constipation in pregnant women is similar to that of nonpregnant patients and medications may be used when diet and lifestyle modifications are not effective. Agents other than bisacodyl are preferred as initial treatment. Stimulant laxatives, including bisacodyl, are not recommended for chronic use, but may be used intermittently when needed (ACG [Christie 2007]).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience abdominal pain, abdominal cramps, or rectal burning (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.